Connect with us


Top Stocks To Buy Now? 3 Consumer Stocks To Watch That Reported Earnings

Should investors be betting on these top consumer-focused stocks?
The post Top Stocks To Buy Now? 3 Consumer Stocks To Watch That Reported Earnings appeared…



Are These The Best Consumer Stocks To Have In Your Portfolio Right Now?

With growing concerns regarding the overall state of the economic recovery from the pandemic, consumer stocks could be worth noting. On the whole, this area of the stock market today has been and still is relevant today. After all, key factors influencing markets today would be inflation, economic growth, and the job market. All of which involve consumers to a certain extent. Sure, while the stock market may be seeing turbulence now, the Labor Department’s latest jobs report suggests that the U.S. labor market holds strong. Evidently, April’s non-farm payroll figures are now in at 428,000, well above consensus estimates of 380,000.

Not to mention, some of the top consumer stocks are pressing forward despite less-than-ideal operating conditions. Take Block (NYSE: SQ) for instance. This leading name in the fintech space posted commendable figures in its latest quarterly earnings report. While the company did not top Wall Street estimates, its Square ecosystem continues to thrive. Throughout the quarter, the gross payment volume (GPV) for the platform was $43.5 billion. This adds up to a year-over-year bump of 31.4%. According to CFO Amrita Ahuja, Block also sees its Cash App and Square solutions posting sequential gross profit growth throughout 2022.

Arguably, not all consumer firms are made equal. In other words, some companies are handling the current macroeconomic headwinds better than others. Nonetheless, even as businesses like Under Armour (NYSE: UAA) feel the heat from supply chain pressures and marketplace uncertainties, some investors could see an opportunity. In the case of Under Armour, the company is currently coming off “a multi-year transformation and after delivering a record year in 2021” and is targeting long-term growth. On that note, could one of these three consumer stocks be top picks in the stock market now?

Consumer Stocks To Buy [Or Sell] Today

Opendoor Technologies Inc.

For starters, we have Opendoor. For the uninitiated, Opendoor, as the name suggests, is a company that operates in the real-estate space. Through its digital marketplace, Opendoor allows consumers to make housing-related transactions. The likes of which range from instant cash offers on homes to property repair orders and relisting solutions. Notably, OPEN stock could be worth checking out in the stock market today thanks to the company’s recent earnings update.

After yesterday’s market close, Opendoor saw green across the board for its first fiscal quarter release. Getting straight to it, the company is boasting earnings of $0.04 alongside revenue of $5.2 billion. For reference, this is versus consensus analyst forecasts of a $0.07 loss per share and revenue of $4.29 billion. Safe to say, these eye-opening beats could potentially put the company’s stock on investors’ radars.

Aside from that, Opendoor is looking at a record quarter overall. This is apparent as the company hit a record-high for quarterly revenue and is seeing year-over-year gains of 590% on this front. Regarding Opendoor’s total home sales count, it is up by 415% over the same period. According to CEO Eric Wu, the company is now focusing on growing its customer base, driving sustainable margin expansion, and operating via a “lowest cost structure.” Through a combination of all these efforts, Wu argues that Opendoor can fuel further growth while protecting its margins. With all this in mind, would you consider OPEN stock a buy?

OPEN stock chart
Source: TD Ameritrade TOS

[Read More] Stock Market Today: Dow Jones, S&P 500 Continues Retreat; Opendoor (OPEN) In Focus After Earnings Beat

DraftKings Inc.

Following that, we have DraftKings, a digital sports entertainment and gaming company that has a wide range of products. This ranges from daily fantasy to regulated gaming, and digital media. The company is a multi-channel provider of sports betting and gaming technologies across 17 countries. It also has an iGaming business in 5 states through its DraftKings brand. The company also reported a strong quarter today.

Diving in, the company posted a revenue of $417 million, a 34% increase compared to a year ago. The company says it delivered significant growth across its key revenue and performance metrics and that it is not seeing any impact from inflationary pressures on customer demand. DraftKings also continues to improve its efficiency by acquiring and retaining customers and it also has a strong pipeline of new jurisdictions to enter. Monthly Unique Payers increased to 2 million customers, an increase of 29% year-over-year.

The company is also now live with mobile sports betting in 17 states, collectively representing approximately 36% of the U.S. population. DraftKings also continued to deepen the content offering for DraftKings Sportsbook, which helps drive customer acquisition, engagement, and retention, by adding micro markets like wagering on the “next field goal” for the NBA and college basketball. All things considered, is DKNG stock a buy right now?

DKNG stock
Source: TD Ameritrade TOS

[Read More] Metaverse Stocks To Buy Today? 4 For Your April Watchlist

DoorDash Inc.

DoorDash is a consumer company that operates an online food ordering and delivery platform. In fact, it is one of the largest delivery companies in the U.S. and enjoys a huge market share. It connects hundreds of thousands of merchants to over 25 million consumers in the U.S., Canada, Australia, and Japan through its local logistics platform. Accordingly, its platform allows local businesses to thrive in today’s “convenience economy,” as the company puts it.

On Thursday, the company reported its first-quarter financials for 2022. Firstly, it posted a revenue of $1.5 billion, growing by 35% year-over-year. This was driven by total orders that grew by 23% year-over-year to $404 million. Secondly, it reported a GAAP gross profit of $662 million, an increase of 34% year-over-year. The company says that it has added more consumers than any quarter since Q1 2021, due in part to the growth of its DashPass members. The growth in Monthly Active Users and average order frequency has helped it gain share in the U.S. Food Delivery category this quarter.

“In the two years from Q1 2020 to Q1 2022, we grew orders in our U.S. Restaurant Marketplace by over 250%, grew category share by 14 percentage points, and significantly increased Contribution Profit in the category. Over this time period, we also substantially increased Contribution Profit as a percentage of Marketplace GOV in the category, despite significant ongoing investments in consumer, Dasher, and merchant acquisition. We drove the increase in Contribution Profit as a percentage of Marketplace GOV largely through efficient operations and our laser focus on execution, which contributed to improvements in quality and network efficiency, and operational leverage,” said CEO Tony Xu. Given this piece of information, is DASH stock worth investing in?

DASH stock
Source: TD Ameritrade TOS

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Top Stocks To Buy Now? 3 Consumer Stocks To Watch That Reported Earnings appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading


Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…



Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading


Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch…



Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch Times (emphasis ours),

An Australian and Swedish investigation has found that among the hundreds of COVID-19 research papers that have been withdrawn, a retracted study linking the drug hydroxychloroquine to increased mortality was the most cited paper.

Hydroxychloroquine sulphate tablets. (Memories Over Mocha/Shutterstock)

With 1,360 citations at the time of data extraction, researchers in the field were still referring to the paper “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” long after it was retracted.

Authors of the analysis involving the University of Wollongong, Linköping University, and Western Sydney Local Health District wrote (pdf) that “most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn.”

“This has serious implications for the reliability of published research and the academic literature, which need to be addressed,” they said.

Retraction is the final safeguard against academic error and misconduct, and thus a cornerstone of the entire process of knowledge generation.”

Scientists Question Findings

Over 100 medical professionals wrote an open letter, raising ten major issues with the paper.

These included the fact that there was “no ethics review” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.”

A bottle of Hydroxychloroquine at the Medicine Shoppe in Wilkes-Barre, Pa on March 31, 2020. Some politicians and doctors were sparring over whether to use hydroxychloroquine against the new coronavirus, with many scientists saying the evidence is too thin to recommend it yet. (Mark Moran/The Citizens’ Voice via AP)

Other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts, which would present skewed results.

They also found that the data that was reportedly from Australian patients did not seem to match data from the Australian government.

Eventually, the study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK.

France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials.

Currently, a total of 337 research papers on COVID-19 have been retracted, according to Retraction Watch.

Further retractions are expected as the investigation of proceeds.

Tyler Durden Sat, 06/03/2023 - 17:30

Read More

Continue Reading


Complying, Not Defying: Twitter And The EU Censorship Code

Complying, Not Defying: Twitter And The EU Censorship Code

Authored by ‘Robert Kogon’ via The Brownstone Institute,

So, word has it that…



Complying, Not Defying: Twitter And The EU Censorship Code

Authored by 'Robert Kogon' via The Brownstone Institute,

So, word has it that Twitter has withdrawn from the EU’s Code of Practice on Disinformation, a fact that appears only to be known thanks to a couple of pissy tweets from EU officials. I cannot help but wonder if this is not finally Elon Musk’s response to the question I asked in my article here several weeks ago: namely, how can a self-styled “free-speech absolutist” be part of a “Permanent Task-Force on Disinformation” that is precisely a creation of the EU’s Code?

But does it matter? The answer is no. The withdrawal of Twitter’s signature from the Code is a highly theatrical, but essentially empty gesture, which will undoubtedly serve to shore up Musk’s free speech bad-boy bona fides, but has virtually no practical consequences. 

This is because: (1) as I have discussed in various articles (for instance, here and here), the effect of the EU’s Digital Services Act (DSA) is to render the hitherto ostensibly voluntary commitments undertaken in the Code obligatory for all so-called Very Large Online Platforms (VLOPs) and (2) as discussed here, the European Commission just designated a whole series of entities as VLOPs that were never signatories of the Code.

Twitter is thus in no different a position than Amazon, Apple and Wikipedia, none of which were ever signatories of the Code, but all of which will be expected by the EU to comply with its censorship requirements on the pain of ruinous fines. 

As EU officials like to put it, the DSA transformed the “code of practice” into a code of conduct: i.e. you had better do it or else.

Compliance is thus not a matter of a signature. The proof of the pudding is in the eating. And the fact of the matter is that Musk and Twitter are complying with the EU’s censorship requirements. Much of the programming that has gone into the Twitter algorithm is obviously designed for this very purpose.

What, for instance, are the below lines of code?

They are “safety labels” that have been included in the algorithm to restrict the visibility of alleged “misinformation.” Furthermore – leaving aside the handy “generic misinfo” catch-all – the general categories of “misinformation” used exactly mirror the main areas of concern targeted by the EU in its efforts to “regulate” online speech: “medical misinfo” in the context of the COVID-19 pandemic, “civic misinfo” in the context of issues of electoral integrity, and “crisis misinfo” in the context of the war in Ukraine.

Indeed, as Elon Musk and his lawyers certainly know, the final version of the DSA includes a “crisis response mechanism,” (Art. 36) which is clearly modeled on the European Commission’s initially ad hoc response to the Ukraine crisis and which requires platforms to take special measures to mitigate crisis-related “misinformation.” 

In its January submission to the EU (see reports archive here), in the section devoted precisely to its efforts to combat Ukraine-war-related “misinformation,” Twitter writes (pp. 70-71): 

“We … use a combination of technology and human review to proactively identify misleading information. More than 65% of violative content is surfaced by our automated systems, and the majority of remaining content we enforce on is surfaced through regular monitoring by our internal teams and our work with trusted partners.”

How is this not compliance? Or at least a very vigorous effort to achieve it? And the methodology outlined is presumably used to “enforce on” other types of “mis-“ or “disinformation” as well.

Finally, what is the below notice, which many Twitter users recently received informing them that they are not eligible to participate in Twitter Ads because their account as such has been labeled “organic misinformation?”

Why in the world would Twitter turn away advertising business? The answer is simple and straightforward: because none other than the EU’s Code of Practice on Disinformation requires it to do so in connection with the so-called “demonetization of disinformation.” 

Thus, section II(d-f) of the Code reads:

(d) The Signatories recognise the need to combat the dissemination of harmful Disinformation via advertising messages and services.

(e) Relevant Signatories recognise the need to take granular and tailored action to address Disinformation risks linked to the distribution of online advertising. Actions will be applicable to all online advertising.

(f) Relevant Signatories recognise the importance of implementing policies and processes not to accept remuneration from Disinformation actors, or otherwise promote such accounts and websites.

So, in short, vis-à-vis the EU and its Code, Twitter is complying, not defying. Removing Twitter’s signature from the Code when its signature is no longer required on the Code anyway is not defiance. Among other things, not labeling content and/or users as “misinformation,” not restricting the visibility of content and/or users so labeled, and accepting advertising from whomever has the money to pay would be defiance.

But the EU’s response to such defiance would undoubtedly be something more than tweets. It would be the mobilization of the entire punitive arsenal contained in the DSA and, in particular, the threat or application of the DSA fines of 6 percent of the company’s global turnover.

It is not enough to (symbolically) withdraw from the Code of Practice to defy the EU. Defying the EU would require Twitter to withdraw from the EU altogether.

Tyler Durden Sat, 06/03/2023 - 10:30

Read More

Continue Reading